Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 69 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Keyword is Bone Density  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Anagnostis, P., Karras S. N., & Goulis D. G. (2014).  Monitoring the efficacy of once-weekly teriparatide. Are bone turnover markers useful in predicting fracture risk?. Curr Med Res Opin. 30(6), 1177-8.
Anagnostis, P., Karagiannis A., Kakafika A. I., Tziomalos K., Athyros V. G., & Mikhailidis D. P. (2009).  Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. Osteoporos Int. 20(2), 197-207.
Anagnostis, P., Vakalopoulou S., Vyzantiadis T-A., Charizopoulou M., Karras S., Goulis D. G., et al. (2014).  The clinical utility of bone turnover markers in the evaluation of bone disease in patients with haemophilia A and B.. Haemophilia. 20(2), 268-75.
Anagnostis, P., Vakalopoulou S., Slavakis A., Charizopoulou M., Kazantzidou E., Chrysopoulou T., et al. (2012).  Reduced bone mineral density in patients with haemophilia A and B in Northern Greece.. Thromb Haemost. 107(3), 545-51.
Anagnostis, P., Siolos P., Gkekas N. K., Kosmidou N., Artzouchaltzi A-M., Christou K., et al. (2019).  Association between age at menopause and fracture risk: a systematic review and meta-analysis.. Endocrine. 63(2), 213-224.
Anagnostis, P., Karras S. N., & Goulis D. G. (2015).  Bone disease in patients with haemophilia A and B--where are we now?. Haemophilia. 21(1), 1-3.
Anagnostis, P., Florentin M., Livadas S., Lambrinoudaki I., & Goulis D. G. (2022).  Bone Health in Patients with Dyslipidemias: An Underestimated Aspect.. Int J Mol Sci. 23(3), 
Anagnostis, P., Karras S. N., Vakalopoulou S., & Terpos E. (2016).  Haemophilia and low bone mass. Ok, but what about fracture risk?. Haemophilia. 22(1), 11-4.
Anagnostis, P., Vyzantiadis T-A., Charizopoulou M., Adamidou F., Karras S., Goulis D. G., et al. (2013).  The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.. Thromb Haemost. 110(2), 257-63.
Anagnostis, P., Gkekas N. K., Potoupnis M., Kenanidis E., Tsiridis E., & Goulis D. G. (2019).  New therapeutic targets for osteoporosis.. Maturitas. 120, 1-6.
Anagnostis, P., Paschou S. A., Gkekas N. N., Artzouchaltzi A-M., Christou K., Stogiannou D., et al. (2018).  Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.. Endocrine. 60(3), 373-383.
Anagnostis, P., Lambrinoudaki I., Kenanidis E., Potoupnis M., Tsiridis E., & Goulis D. G. (2019).  Drug holidays in osteoporosis treatment: mind the gaps!. Osteoporos Int. 30(12), 2523-2524.
Anagnostis, P., Vakalopoulou S., Karras S., Charizopoulou M., & Garipidou V. (2014).  The role of arthropathy in the development of osteoporosis in patients with haemophilia: do we need more?. Haemophilia. 20(1), e83-5.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Anastasilakis, A. D., Polyzos S. A., Avramidis A., Papatheodorou A., & Terpos E. (2009).  Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.. Horm Metab Res. 41(7), 559-62.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Karathanasi E., & Efstathiadou Z. (2011).  Coincidence of severe primary hyperparathyroidism and primary hypothyroidism in a postmenopausal woman with low bone mass--initial conservative management.. J Musculoskelet Neuronal Interact. 11(1), 77-80.
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Bisbinas I., Katsarou A., et al. (2014).  Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.. Osteoporos Int. 25(5), 1633-42.
Anastasilakis, A. D., Polyzos S. A., Goulis D. G., Slavakis A., Efstathiadou Z., Kita M., et al. (2008).  Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis.. Endocr J. 55(3), 613-6.
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Bisbinas I., Sakellariou G. T., Gkiomisi A., et al. (2012).  The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.. Clin Endocrinol (Oxf). 77(6), 816-22.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, A. D., Polyzos S. A., Avramidis A., Toulis K. A., Papatheodorou A., & Terpos E. (2010).  The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.. Clin Endocrinol (Oxf). 72(6), 752-7.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Saridakis Z. G., Digkas D., Bisbinas I., et al. (2015).  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.. Osteoporos Int. 26(10), 2521-7.
Anastasilakis, A. D., Toulis K. A., Polyzos S. A., & Terpos E. (2009).  RANKL inhibition for the management of patients with benign metabolic bone disorders.. Expert Opin Investig Drugs. 18(8), 1085-102.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές